MannKind (MNKD) awards EVP Singh performance RSUs and stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
MannKind Corp reported new equity awards for EVP Technical Operations Sanjay R. Singh. He received 221,000 performance-based restricted stock units, each tied to one common share, that vest on January 15, 2029 with payout ranging from 0% to 300% of target based on relative total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028. He was also granted options on 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and the remainder in equal quarterly installments through 2031, expiring March 23, 2036. These are compensation-related grants, not open-market trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Singh Sanjay R
Role
EVP Technical Operations
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Restricted Stock Unit | 221,000 | $0.00 | -- |
| Grant/Award | Employee Stock Option (right to buy) | 217,000 | $0.00 | -- |
Holdings After Transaction:
Performance Restricted Stock Unit — 221,000 shares (Direct);
Employee Stock Option (right to buy) — 217,000 shares (Direct)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.
FAQ
What insider transactions did MannKind (MNKD) report for Sanjay R. Singh?
MannKind reported equity awards for EVP Sanjay R. Singh, not open-market trades. He received 221,000 performance-based restricted stock units and options on 217,000 shares, both tied to MannKind common stock, as part of his long-term incentive compensation package.
How do the MannKind (MNKD) performance RSUs for Sanjay R. Singh vest?
The 221,000 performance RSUs vest on January 15, 2029, with payout from 0% to 300% of target. The outcome depends on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index between April 1, 2026 and December 31, 2028.
What are the key terms of Sanjay R. Singh’s MannKind (MNKD) stock options?
Sanjay R. Singh received options on 217,000 MannKind shares at a $2.44 exercise price. These options vest 25% on March 23, 2027, then 1/16 each quarter thereafter, and expire on March 23, 2036, providing long-dated equity-based compensation.
Are the MannKind (MNKD) Form 4 transactions open-market buys or sells?
The Form 4 transactions are equity grants, not market trades. Both the performance RSUs and stock options were awarded as compensation, with zero-dollar grant price, so they do not represent Sanjay R. Singh buying or selling shares in the open market.
What performance measure determines MannKind (MNKD) RSU payout for Sanjay R. Singh?
Payout depends on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index. Below the 25th percentile pays 0% of target, while the 90th percentile or higher pays 300%, with interpolation between levels, aligning awards with relative shareholder returns.